<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881581</url>
  </required_header>
  <id_info>
    <org_study_id>CDCPChina001</org_study_id>
    <nct_id>NCT01881581</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS</brief_title>
  <official_title>A Phase I Double-Blind Study to Evaluate the Safety and Immunogenicity of HIV Prime/Boost Vaccine Using DNA and MVA for HIV-1/AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes for Food and Drug Control, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind placebo-controlled dose-escalation clinical trial to
      evaluate the safety and the immunogenicity of DNA and modified vaccinia virus Ankara (MVA)
      HIV-1 vaccines in subjects receiving stable highly active antiretroviral therapy (HAART) who
      have an HIV-1 RNA &lt; 50 copies/mm3 and CD4+ T cells count ≥ 350 cells/mm3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected patients treated with antiretroviral therapy for prolonged periods of time may
      show decreased levels of HIV-specific immune responses. In these patients, a prime-boost
      vaccine strategy may induce both humoral and cell-mediated immunity. The hypothesis of this
      study is that the vaccine strategy selected will be both safe and immunogenic in the patient
      population being tested.

      Patients continue antiretroviral medications throughout the course of this study. Three
      groups of patients receive dose-escalation (0.5mg, 2mg or 4mg) intramuscular injections of
      DNA vaccine (D-GPEi) respectively, the other three groups of patients receive dose-escalation
      (3×10^7pfu, 1×10^8pfu or 3×10^8pfu) intradermal injections of MVA vaccine (M-GPE), two weeks
      post immunization of lower dose, if the vaccine is safe and well tolerant, the next dose of
      immunization will begin. After the maximum tolerated dose of DNA and MVA is identified, DNA
      prime/ MVA boosting will be tested in another two groups of patients. Lower or the maximum
      tolerated dose of D-GPEi was used at week 0 and 1, lower or the maximum tolerated dose of
      M-GPE was used at week 2 and 3, patients are monitored for safety 72 hours after each
      immunization. In addition, each patient records adverse events in a diary. Patients have
      regular physical exams, pregnancy tests, and blood drawn for virologic and immunologic
      assessments. The induction of HIV-specific responses will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of local and systemic adverse events</measure>
    <time_frame>8 months</time_frame>
    <description>To evaluate the safety and tolerance of a DNA and a replication-defective MVA vaccine expressing HIV-1 gag-pol and env in HIV-1 infected subjects on highly active antiretroviral therapy.
Frequency and severity of adverse events, laboratory abnormalities, and local and systemic reactogenicity signs and symptoms following vaccinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of vaccine</measure>
    <time_frame>14 months</time_frame>
    <description>Changes in CD4+ and CD8+ T-cell counts pre- and post-immunization and between the vaccine and placebo groups Changes in viral load pre- and post-immunization and between the vaccine and placebo groups Magnitude and breadth of HIV-1 specific CD8+ T cell responses as determined by interferon-γ(IFN-γ) enzyme-linked immunospot (ELISPOT) using overlapping HIV peptides for gag, pol and env Changes in HIV-1 Gp160-specific antibody responses pre- and post-immunization and between the vaccine and placebo groups</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>Lower dose DNA or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose DNA or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose DNA or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower dose MVA or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100μL lower dose M-GPE (3×10^7pfu) or Saline solution at weeks 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose MVA or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100μL medium dose M-GPE (1×10^8pfu) or Saline solution at weeks 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose MVA or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300μL high dose M-GPE (3×10^8pfu) or Saline solution at weeks 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose DNA+MVA or Placebo control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose DNA+MVA or Placebo control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>Saline Solution is used as control in all arms.</description>
    <arm_group_label>Lower dose DNA or Placebo</arm_group_label>
    <arm_group_label>Medium dose DNA or Placebo</arm_group_label>
    <arm_group_label>High dose DNA or Placebo</arm_group_label>
    <arm_group_label>Lower dose MVA or Placebo</arm_group_label>
    <arm_group_label>Medium dose MVA or Placebo</arm_group_label>
    <arm_group_label>High dose MVA or Placebo</arm_group_label>
    <arm_group_label>Low dose DNA+MVA or Placebo control</arm_group_label>
    <arm_group_label>High dose DNA+MVA or Placebo control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>D-GPEi</intervention_name>
    <description>D-GPEi is used in Arm A,B,C,G and H.</description>
    <arm_group_label>Lower dose DNA or Placebo</arm_group_label>
    <arm_group_label>Medium dose DNA or Placebo</arm_group_label>
    <arm_group_label>High dose DNA or Placebo</arm_group_label>
    <arm_group_label>Low dose DNA+MVA or Placebo control</arm_group_label>
    <arm_group_label>High dose DNA+MVA or Placebo control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-GPE</intervention_name>
    <description>M-GPE is used in Arm D,E,F,G and H</description>
    <arm_group_label>Lower dose MVA or Placebo</arm_group_label>
    <arm_group_label>Medium dose MVA or Placebo</arm_group_label>
    <arm_group_label>High dose MVA or Placebo</arm_group_label>
    <arm_group_label>Low dose DNA+MVA or Placebo control</arm_group_label>
    <arm_group_label>High dose DNA+MVA or Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are willing to participate this study and available for follow-up for the duration of
             the study.

          -  Men and women aged 18-50 years.

          -  Are HIV-positive.

          -  Have been taking stable anti-HIV drugs for at least 6 months.

          -  CD4 count ≥ 350 cells/mm3

          -  Plasma viral load &lt; 50 copies/ml.

          -  Willing to use acceptable forms of contraception at least 21 days prior to first
             vaccination until 56 days after the last vaccination.

        Exclusion Criteria:

          -  Pregnancy or breast-feeding.

          -  History of previous vaccination with an HIV-1 vaccine.

          -  Use of immunoinhibitory agents, such as corticosteroids or cytotoxic drugs by oral
             administration, injection route or inhalation route within 6 months of study entry
             (But corticosteroids used for allergic rhinitis and skin topical application of
             corticosteroids were not included); Use of immunomodulatory agents including but not
             limited to interleukin-2(IL-2） and granulocyte-macrophage colony-stimulating factor
             (GM-CSF) within 30 days of study entry.

          -  Use of blood products within 3 months of study entry.

          -  Use of other experimental drugs within 3 months of study entry.

          -  Any immunization within 3 months of study entry.

          -  Comply with any of the following items： Active pulmonary tuberculosis； History of
             serious adverse reaction to other vaccines； Serious asthma； Have untreated thyroid
             disease; Syphilis

          -  Laboratory values（Comply with any of the following items）:

        Hemoglobin &lt; 100 g/L (male subjects)，&lt;90 g/L (female subjects)； Absolute neutrophil count ≤
        1000 cells/mm3； Serum creatinine ≥15 mg/L，endogenous creatinine clearance rate &lt;50 ml/min；
        alanine aminotransferase（ALT）, aspartate aminotransferase(AST) ≥3× upper limit of normal
        range； Total bilirubin ≥2× upper limit of normal range

          -  Clinically significant electrocardiogram changes.

          -  Hypertension ( If it is well controlled by medication and is less than 150/100mmHg ,
             should not be excluded) and other cardiac disease；

          -  Any medical, psychiatric, social condition, occupational reason judged by the
             investigator that would limit the evaluation of a subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingwang Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijng Ditan Hospital of Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rongmeng Jiang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijng Ditan Hospital of Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi Zeng</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Viral Disease Control and Prevention, China CDC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xia Feng, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Viral Disease Control and Prevention, China CDC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ke Xu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Viral Disease Control and Prevention, China CDC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Ditan Hospital of Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingwang Li</last_name>
      <phone>15611973658</phone>
      <email>ditanlxw@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Xingwang Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rongmeng Jiang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2013</study_first_submitted>
  <study_first_submitted_qc>June 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centers for Disease Control and Prevention, China</investigator_affiliation>
    <investigator_full_name>Yi Zeng</investigator_full_name>
    <investigator_title>Departement Director</investigator_title>
  </responsible_party>
  <keyword>Therapeutic</keyword>
  <keyword>Vaccine</keyword>
  <keyword>HIV</keyword>
  <keyword>MVA</keyword>
  <keyword>DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

